Bank of New York Mellon
PRVL

Bank of New York Mellon’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Bank of New York Mellon’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-33,526
Closed -$773K – 4404
2020
Q4 		$773K Sell
33,526
-95,826
-74% -$1.21M ﹤0.01% 3395
2020
Q3 		$1.32M Sell
129,352
-68,116
-34% -$914K ﹤0.01% 2948
2020
Q2 		$2.94M Sell
197,468
-27,686
-12% -$426K ﹤0.01% 2470
2020
Q1 		$2.75M Buy
225,154
+11,664
+5% +$186K ﹤0.01% 2381
2019
Q4 		$3.38M Buy
213,490
+3,419
+2% +$43.6K ﹤0.01% 2534
2019
Q3 		$2.58M Buy
+210,071
New +$2.38M ﹤0.01% 2616

Bank of New York Mellon's PRVL Position: Q1 2021 in Review

Bank of New York Mellon sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 33,526 shares — an estimated $773K sold.

Bank of New York Mellon first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $3.38M in Q4 2019. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Bank of New York Mellon reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 33,526 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $773K.
  • Bank of New York Mellon first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • Bank of New York Mellon's Prevail Therapeutics Inc. Common Stock position peaked at $3.38M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Bank of New York Mellon's 13F filing for Q1 2021, filed 13 May 2021.